🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 88 of 173

  1. US 9364505

    Therapeutic composition for treatment of glioblastoma

    Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9364501

    Chlorite in the treatment of neurodegenerative disease

    Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9364509

    Therapeutic uses of mastic gum fractions

    Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9364406

    Open chained or fused 1,1′-alkylene-bis-uracil derivatives, useful in skin UV-protection

    Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9365621

    Method for preventing neoplastic transformation by inhibition of retinoblastoma protein inactivation

    Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9365581

    Deuterated amlexanox

    Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9364443

    Compositions and methods for drug delivery

    Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9358283

    Diatom-based vaccines

    Expires Mon Jun 02 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9358249

    Use of Pateamine A for the treatment of age-related muscle wasting

    Expires Mon Jun 02 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9359309

    Synthesis of syrbactin proteasome inhibitors

    Expires Mon Jun 02 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9359360

    TLR agonists

    Expires Mon Jun 02 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9359196

    Antiproliferative compositions comprising curcumin analogs and methods of producing and using same

    Expires Mon Jun 02 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9351490

    Selectively targeted antimicrobial peptides and the use thereof

    Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9351984

    Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity

    Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9353178

    Stem cell factor inhibitor

    Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9353352

    Embryonic stem cell specific microRNAs promote induced pluripotency

    Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9353094

    Substituted quinoxalines as kinase inhibitors

    Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9353075

    Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA)

    Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9352015

    Antimicrobial peptides

    Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9345726

    CD117+ cells and uses thereof

    Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9347143

    Membrane template synthesis of microtube engines

    Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9346865

    Antimicrobial peptides and methods of use

    Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9346866

    Inhibition of tace activity with cyclic peptides

    Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9346858

    Proteins with repetitive Bacterial-Ig-like (Big) domains present in Leptospira species

    Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9345781

    Targeted dendrimer-drug conjugates

    Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9345790

    Cobalt-based MRI contrast agent and imaging system

    Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9341626

    Selective cytopheresis devices and related methods thereof

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9340572

    Taccalonolide microtubule stabilizers

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9339528

    Methods for treating epithelium trauma of the intestinal mucosa using interleukin-1 receptor antagonist

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9339482

    Methods to treat dysregulated blood glucose disorders

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9339433

    Methods of diagnosing and treating neonatal reversion to fetal consciousness

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9339440

    Thermo-kinetic mixing for pharmaceutical applications

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9340782

    Antimir-451 for the treatment of polycythemias

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9340785

    Selective inhibition of polyglutamine protein expression

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9340769

    Methods and compositions for treating P. acnes

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9340606

    Immunization with amyloid-beta oligomers

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9333171

    Controlled-release CNS modulating compositions and methods for the treatment of otic disorders

    Expires Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9333245

    Methods and compositions for treating wounds and reducing the risk of incisional hernias

    Expires Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9333258

    Fine spatiotemporal control of fat removal using NIR light

    Expires Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9333248

    Methods and composition related to Th-1 dendritic cells

    Expires Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9334250

    Multifunctional radical quenchers for the treatment of mitochondrial dysfunction

    Expires Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9334306

    Leukemia stem cell targeting ligands and methods of use

    Expires Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9333264

    Biocompatible polymeric nanoparticles degrade and release cargo in response to biologically relevant levels of hydrogen peroxide

    Expires Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9333259

    Selective fat removal using NIR light and nanoparticles

    Expires Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9327016

    Enzymes and methods for cleaving N-glycans from glycoproteins

    Expires Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9328324

    System, method and devices for tissue-based diagnosis

    Expires Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9328148

    Campylobacter immunogenic compositions and uses thereof

    Expires Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9327036

    DNA-cell conjugates

    Expires Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.